文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

XXX试验两年结果:单次消融放疗治疗局限期前列腺癌的安全性、PSA动力学与患者报告结局纵向分析

Two-Year Outcomes of the XXX Trial: Longitudinal Analysis of Safety, PSA Kinetics, and Patient-Reported Outcomes.
PubMed 文献 · Pract Radiat Oncol · 2026-10-22

单中心前瞻性研究纳入30例不良中危或选择性高危局限期前列腺癌患者,接受单次24 Gy消融放疗联合雄激素剥夺治疗。2年时无≥G3不良事件,累积G2泌尿和胃肠道不良事件分别为23%和7%,生化无复发生存率100%,患者报告结局无临床意义恶化。

要点

  • 单次24 Gy消融放疗联合ADT在局限期前列腺癌中可行且耐受良好。
  • 2年累积G2泌尿和胃肠道不良事件分别为23%和7%,无≥G3事件。
  • 2年生化无复发生存率100%,PSA持续显著下降,mpMRI证实局部影像学控制。

核心结论

  • 单次24 Gy消融放疗联合ADT在不良局限期前列腺癌中可行且耐受良好,2年≥G2不良事件率低且生活质量基本维持。

研究设计与样本

  • 单中心前瞻性研究,纳入30例不良中危或选择性高危局限期前列腺癌患者,接受前列腺和精囊单次24 Gy放疗联合ADT。

主要发现

  • 2年时无≥G3不良事件,累积G2泌尿和胃肠道不良事件分别为23%和7%,2年时点患病率分别为10%和3%。
  • 纵向分析显示安全性总体稳定,基线IPSS较高和膀胱三角D1cc较高与泌尿不良事件增加显著相关。
  • 患者报告结局中泌尿域有统计学显著变化,但效应量低于最小重要差异阈值,无临床意义恶化。
  • 2年生化无复发生存率100%,PSA随时间持续显著下降,mpMRI证实局部影像学控制。
  • 接受ADT的患者中76%出现睾酮恢复。

临床怎么用

  • 单次24 Gy消融放疗可作为不良局限期前列腺癌的一种可行治疗选择,需关注基线IPSS和膀胱三角剂量对泌尿毒性影响。

局限性

  • 早期肿瘤学结果需更长随访和对照验证确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the 2-year incidence and longitudinal trajectory of grade (G) ≥2 genitourinary (GU) and gastrointestinal (GI) adverse events (AEs) following single-dose ablative radiotherapy (SDRT) for organ-confined prostate cancer (PCa), alongside associated changes in patient-reported outcomes (PROs) and PSA kinetics. METHODS: XXX (XXX) is a single-institution prospective study enrolling patients with unfavorable intermediate-risk or selected high-risk organ-confined PCa treated with SDRT delivering 24 Gy in one fraction to the prostate and seminal vesicles. Treatment incorporated urethra-sparing and intrafraction motion control and was delivered on a linear accelerator using a 10-MV flattening filter-free single partial arc in combination with androgen deprivation therapy (ADT). AEs were graded using CTCAE v5.0. PSA and testosterone were monitored longitudinally, and scheduled multiparametric MRI (mpMRI) were performed to assess radiological response. PROs were assessed using EORTC QLQ-C30, QLQ-PR25, IPSS, and IIEF questionnaires. Mixed-effects models evaluated longitudinal trajectories and associations with baseline and dosimetric factors. RESULTS: Thirty patients were treated. At 2 years, no ≥G3 AEs were observed. Cumulative G2 GU and GI AEs were 23% and 7%, respectively. Two years point prevalent G2 GU and GI AEs were 10% and 3%, respectively. Longitudinal analysis showed an overall stable safety profile, with higher baseline IPSS and bladder trigone D1cc significantly associated with higher GU AEs. PRO analyses demonstrated statistically significant changes in urinary domains, although effect sizes remained below minimal important difference thresholds, indicating no clinically meaningful deterioration. Baseline symptom burden strongly predicted long-term PROs trajectories. Biochemical relapse-free survival was 100% at 2 years, with a consistent and significant PSA decline over time and local radiological control confirmed by mpMRI. Testosterone recovery occurred in 76% of patients receiving ADT. CONCLUSIONS: Single-fraction 24 Gy SDRT combined with ADT was feasible and well tolerated, with low rates of ≥G2 AEs and largely maintained quality of life at 2 years in patients with unfavorable localized prostate cancer. Early oncologic outcomes are encouraging but require confirmation with longer follow-up and comparative validation.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Arcangeli S, Faccenda V, Ferrario F, et al. Two-Year Outcomes of the XXX Trial: Longitudinal Analysis of Safety, PSA Kinetics, and Patient-Reported Outcomes. Pract Radiat Oncol. 2026. PMID: 42913916. doi:10.1016/j.prro.2026.10.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。